The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Open accessAbstract
BACKGROUND: Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use. METHODS: We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department (study baseline). The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received hydroxychloroquine with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score. RESULTS: Of 1446 consecutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation and were excluded from the analysis. Of the remaining 1376 patients, during a median follow-up of 22.5 days, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days); 45.8% of the patients were treated within 24 hours after presentation to the emergency department, and 85.9% within 48 hours. Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive hydroxychloroquine (median ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, 223 vs. 360). Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation). In the main analysis, there was no significant association between hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32). Results were similar in multiple sensitivity analyses. CONCLUSIONS: In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 are needed. (Funded by the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“First, we used multivariable regression models with inverse probability weighting to minimize the effects of confounding by indication [27,28].”
From Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study (2021) · cites this paper as [28]
In the citing paper
“To help account for the nonrandomized prescription of antidepressants and reduce the effects of confounding, the primary analyses used a propensity score analysis with inverse probability weighting [27,28].”
From Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study (2021) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Esteves-Vieira, V., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedMultiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L. Y., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,696
Devaux, C. A., Rolain, J., Colson, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105938 · Cited by 1,122
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trialPreprint
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 861
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Chen, J., Liu, D., Liu, L., Liu, P., Xu, Q., Xia, L., Ling, Y., Huang, D. F., Song, S., Zhang, D., et al. (2020) · PubMed Central · doi:10.3785/j.issn.1008-9292.2020.03.03 · Cited by 662
Fantini, J., Scala, C. D., Chahinian, H., & Yahi, N. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105960 · Cited by 566
Mechanism of action of hydroxychloroquine as an antirheumatic drug
Fox, R. I. (1993) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(10)80012-5 · Cited by 430
Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral Activities
Biot, C., Daher, W., Leleu‐Chavain, N., Fandeur, T., Khalife, J., Dive, D., & Clercq, E. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0601856 · Cited by 318
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,000
Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
Bonam, S. R., Kaveri, S. V., Sakuntabhai, A., Gilardin, L., & Bayry, J. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100016 · Cited by 130
Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study
Abd-Elsalam, S. M., Esmail, E. S., Khalaf, M. A., Abdo, E. F., Medhat, M. A., Ghafar, M. S. A. E., Ahmed, O. A., Soliman, S., Serangawy, G. N., & Alboraie, M. A. A. (2020) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.20-0873 · Cited by 130
RetractedBai, C., Chotirmall, S. H., Rello, J., Alba, G. A., Ginns, L. C., Krishnan, J. A., Rogers, R., Bendstrup, E. M., Burgel, P., Chalmers, J. D., et al. (2020) · European Respiratory Review · doi:10.1183/16000617.0287-2020 · Cited by 130
Bepridil is potent against SARS-CoV-2 in vitro
Vatansever, E. C., Yang, K. S., Drelich, A. K., Kratch, K. C., Cho, C.-C., Rayavara, K., Hsu, J. C., Mellott, D. M., Xu, S., Tseng, C.-T. K., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012201118 · Cited by 130
Ko, M., Jeon, S., Ryu, W., & Kim, S. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26397 · Cited by 126
Sadeghı, A., Asgari, A., Norouzi, A., Kheiri, Z., Anushirvani, A., Montazeri, M., Hosamirudsai, H., Afhami, S., Akbarpour, E., Aliannejad, R., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa334 · Cited by 125
Elavarasi, A., Prasad, M., Seth, T., Sahoo, R. K., Madan, K., Nischal, N., Soneja, M., Sharma, A., Maulik, S. K., Shalimar, S., et al. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06146-w · Cited by 125
Hesperidin Is a Potential Inhibitor against SARS-CoV-2 Infection
Cheng, F., Huynh, T. K., Yang, C., Hu, D.-W., Shen, Y., Tu, C., Wu, Y., Tang, C., Huang, W., Chen, Y., et al. (2021) · Nutrients · doi:10.3390/nu13082800 · Cited by 124
Falavigna, M., Colpani, V., Stein, C., Azevedo, L. C. P., Bagattini, Â. M., de Brito, G. V., Chatkin, J. M., Cimerman, S., Corradi, M. D. F. D. B., da Cunha, C. A., et al. (2020) · Revista Brasileira de Terapia Intensiva · doi:10.5935/0103-507x.20200039 · Cited by 122
Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial
Darazam, I. A., Shokouhi, S., Pourhoseingholi, M. A., Irvani, S. S. N., Mokhtari, M., Shabani, M., Amirdosara, M., Torabinavid, P., Golmohammadi, M., Hashemi, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-86859-y · Cited by 122
Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19
Farhadian, S., Glick, L. R., Vogels, C. B. F., Thomas, J., Chiarella, J., Casanovas‐Massana, A., Zhou, J., Odio, C. D., Vijayakumar, P., Geng, B., et al. (2020) · BMC Neurology · doi:10.1186/s12883-020-01812-2 · Cited by 121
Catteau, L., Dauby, N., Montourcy, M., Bottieau, E., Hautekiet, J., Goetghebeur, E. J. T., van Ierssel, S. H., Duysburgh, E., Oyen, H. J. V., Wyndham-Thomas, C., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106144 · Cited by 120
Pathogenesis, Clinical Manifestations and Complications of COVID-19
Kordzadeh-Kermani, E., Khalili, H., & Karimzadeh, I. (2020) · Future Microbiology · doi:10.2217/fmb-2020-0110 · Cited by 121
Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019
Bansal, P., Goyal, A., Cusick, A. S., Lahan, S., Dhaliwal, H. S., Bhyan, P., Bhattad, P. B., Aslam, F., Ranka, S., Dalia, T., et al. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1839959 · Cited by 119
SARS‐CoV‐2: A comprehensive review from pathogenicity of the virus to clinical consequences
Lotfi, M., & Rezaei, N. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26123 · Cited by 118
Biomarkers of COVID-19 and technologies to combat SARS-CoV-2
Zhang, L., & Guo, H. (2020) · Advances in Biomarker Sciences and Technology · doi:10.1016/j.abst.2020.08.001 · Cited by 118
Considerations for Heart Failure Care During the COVID-19 Pandemic
DeFilippis, E. M., Reza, N., DONALD, E. M., Givertz, M. M., Lindenfeld, J., & Jessup, M. L. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.05.006 · Cited by 117
Huang, M., Li, M., Xiao, F., Pang, P., Liang, J., Tang, T., Liu, S., Chen, B., Shu, J., You, Y., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa113 · Cited by 117
Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2–Priming Protease TMPRSS2
Azouz, N. P., Klingler, A. M., Callahan, V., Akhrymuk, I. V., Elez, K., Raich, L., Henry, B. M., Benoit, J. L., Benoit, S. W., Noé, F., et al. (2021) · Pathogens and Immunity · doi:10.20411/pai.v6i1.408 · Cited by 117
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Zhou, Y., Xie, Y., Tang, L., Pu, D., Zhu, Y., Liu, J., & Ma, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00733-x · Cited by 116
Zhang, G., Cong, Y., Liu, F., Sun, J., Zhang, J., Cao, G., Zhou, L., Yang, W., Song, Q., Wang, F., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01177-2 · Cited by 120
Godman, B., Haque, M., Islam, S., Iqbal, S., Urmi, U. L., Kamal, Z. M., Shuvo, S. N., Rahman, A., Kamal, M., Haque, M., et al. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.585832 · Cited by 114
Derwand, R., Scholz, M., & Zelenko, V. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106214 · Cited by 113
Zhang, Y., Coats, A. J. S., Zheng, Z., Adamo, M., Ambrosio, G., Anker, S. D., Butler, J., Xu, D., Mao, J., Khan, M. S., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1915 · Cited by 112
Is hydroxychloroquine beneficial for COVID-19 patients?
Li, X., Wang, Y., Agostinis, P., Rabson, A. B., Melino, G., Carafoli, E., Shi, Y., & Sun, E. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2721-8 · Cited by 111
Alessi, J., de Oliveira, G. B., Schaan, B. D., & Teló, G. H. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00583-7 · Cited by 111
Ghazy, R. M., Almaghraby, A. M., Shaaban, R., Kamal, A., Beshir, H., Moursi, A., Ramadan, A., & Taha, S. H. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-77748-x · Cited by 111
Chiotos, K., Hayes, M., Kimberlin, D. W., Jones, S. B., James, S. H., Pinninti, S. G., Yarbrough, A. H., Abzug, M. J., MacBrayne, C. E., Soma, V. L., et al. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa115 · Cited by 111
Stigma & dirty work: In-group and out-group perceptions of essential service workers during COVID-19
Mejia, C., Pittman, R., Beltramo, J. M. D., Horan, K. A., Grinley, A., & Shoss, M. K. (2020) · International Journal of Hospitality Management · doi:10.1016/j.ijhm.2020.102772 · Cited by 111
Castelnuovo, A. F. D., Costanzo, S., Antinori, A., Berselli, N., Blandi, L., Bruno, R., Cauda, R., Guaraldi, G., Menicanti, L., My, I., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.08.019 · Cited by 108
Hydroxychloroquine and COVID-19: a Rheumatologist’s Take on the Lessons Learned
Udupa, A., Leverenz, D. L., Balevic, S. J., Sadun, R. E., Tarrant, T. K., & Rogers, J. L. (2021) · Current Allergy and Asthma Reports · doi:10.1007/s11882-020-00983-9 · Cited by 108
Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine
Gies, V., Bekaddour, N., Dieudonné, Y., Guffroy, A., Frenger, Q., Gros, F., Rodero, M. P., Herbeuval, J., & Korganow, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01409 · Cited by 106
Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2
Satarker, S., Ahuja, T. N., Banerjee, M., Vignesh Balaji, E., Dogra, S. S., Agarwal, T., & Nampoothiri, M. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00231-8 · Cited by 106
Khalifa, S. A. M., Yosri, N., El-Mallah, M. F., Ghonaim, R., Guo, Z., Musharraf, S. G., Du, M., Khatib, A., Xiao, J., Saeed, A., et al. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153311 · Cited by 106
Simeprevir Potently Suppresses SARS-CoV‑2 Replication and Synergizes with Remdesivir
Lo, H. S., Hui, K. P. Y., Lai, H. M., He, X., Khan, K. S., Kaur, S., Huang, J., Li, Z., Chan, A., Cheung, H. H.-Y., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01186 · Cited by 104
Orellana, J. D. Y., Jacques, N., Leventhal, D. G. P., Marrero, L., & Morón-Duarte, L. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275333 · Cited by 104
Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis
Rezagholizadeh, A., Khiali, S., Sarbakhsh, P., & Entezari‐Maleki, T. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173926 · Cited by 103
SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping
Kaur, G., Lungarella, G., & Rahman, I. (2020) · Journal of Inflammation · doi:10.1186/s12950-020-00250-8 · Cited by 102
Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence
Lin, H., Cho, S., Aravamudan, V. M., Sanda, H., Palraj, R., Molton, J. S., & Venkatachalam, I. (2021) · Infection · doi:10.1007/s15010-020-01557-7 · Cited by 101
Kurihara, C., Manerikar, A. J., Querrey, M., Felicelli, C., Yeldandi, A. V., Garza‐Castillon, R., Lung, K. C., Kim, S., Ho, B., Tomic, R., et al. (2022) · JAMA · doi:10.1001/jama.2022.0204 · Cited by 101
Comparison of COVID-19 and influenza characteristics
Bai, Y., & Tao, X. (2021) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2000479 · Cited by 100
Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience
Bossini, N., Alberici, F., Delbarba, E., Valerio, F., Manenti, C., Possenti, S., Econimo, L., Maffei, C., Pola, A., Terlizzi, V., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16176 · Cited by 99
Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?
Vela, J. M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.582310 · Cited by 99
The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness
Coopersmith, C. M., Antonelli, M. M., Bauer, S. R., Deutschman, C. S., Evans, L., Ferrer, R., Hellman, J., Jog, S., Kesecioğlu, J., Kissoon, N. “., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000004895 · Cited by 99
Review of trials currently testing treatment and prevention of COVID-19
Fragkou, P. C., Belhadi, D., Peiffer‐Smadja, N., Moschopoulos, C. D., Lescure, F.-X., Janocha, H., Karofylakis, E., Yazdanpanah, Y., Mentré, F., Skevaki, C. L., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.05.019 · Cited by 98
Devpura, G., Tomar, B. S., Nathiya, D., Sharma, A., Bhandari, D., Haldar, S., Balkrishna, A., & Varshney, A. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153494 · Cited by 98
Psychopharmacology of COVID-19
Bilbul, M., Paparone, P., Kim, A. M., Mutalik, S. P., & Ernst, C. L. (2020) · Psychosomatics · doi:10.1016/j.psym.2020.05.006 · Cited by 97
Outbreak of COVID-19: An emerging global pandemic threat
Peng, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110499 · Cited by 98
A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals
Chitalia, V. C., & Munawar, A. H. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02476-9 · Cited by 96
A Bibliometric Network Analysis of Coronavirus during the First Eight Months of COVID-19 in 2020
Furstenau, L. B., Rabaioli, B., Sott, M. K., Cossul, D., Bender, M. S., Farina, E. M. J. D. M., Filho, F. N. B., Severo, P. P., Dohan, M. S., & Bragazzi, N. L. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18030952 · Cited by 96
Yasui, Y., Yasui, H., Suzuki, K., Saitou, T., Yamamoto, Y., Ishizaka, T., Nishida, K., Yoshihara, S., Gohma, I., & Ogawa, Y. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.09.008 · Cited by 95
Khamis, F. A., Naabi, H. A., Lawati, A. A., Ambusaidi, Z., Sharji, M. A., Barwani, U. A., Pandak, N., Balushi, Z. Y. A., Bahrani, M. A., Salmi, I. A., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.11.008 · Cited by 95
SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigen
Wang, Y., Wang, L., Cao, H., & Liu, C. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26320 · Cited by 94
Late onset infectious complications and safety of tocilizumab in the management of COVID‐19
Pettit, N. N., Nguyen, C. T., Mutlu, G. M., Wu, D., Kimmig, L. M., PITRAK, D. L., & Pursell, K. J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26429 · Cited by 93
Hu, K., Wang, M. E., Zhao, Y., Zhang, Y., Wang, T., Zheng, Z., Li, X., Zeng, S., Zhao, D., Li, H., et al. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00258-7 · Cited by 92
Kasgari, H. A., Moradi, S., Shabani, A. M., Babamahmoodi, F., Badabi, A. R. D., Davoudi, L., Alikhani, A., Hedayatizadeh‐Omran, A., Saeedi, M., Merat, S., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa332 · Cited by 92
Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports
Soumya, R. S., Unni, T. G., & Raghu, K. G. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07073-y · Cited by 92
COVID-19 Digital Health Innovation Policy: A Portal to Alternative Futures in the Making
Bayram, M., Springer, S., Garvey, C. K., & Özdemir, V. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0089 · Cited by 91
Das, S., Bhowmick, S., Tiwari, S., & Sen, S. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00927-1 · Cited by 90
Hultcrantz, M. L., Richter, J. R., Rosenbaum, C. A., Patel, D., Smith, E. L., Korde, N., Lu, S. X., Mailankody, S., Shah, U. A., Lesokhin, A. M., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0102 · Cited by 91
Predictors and outcomes of healthcare-associated infections in COVID-19 patients
Kumar, G., Adams, A., Herrera, M., Raybon-Rojas, E., Singh, V., Sakhuja, A., Meersman, M., Dalton, D., Kethireddy, S., Nanchal, R. S., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.11.135 · Cited by 90
Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians
Porta, A. D., Bornstein, K., Coye, A., Montrief, T., Long, B., & Parris, M. A. (2020) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.07.030 · Cited by 88
Malaria and COVID-19: Common and Different Findings
Di Gennaro, F., Marotta, C., Locantore, P., Pizzol, D., & Putoto, G. (2020) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed5030141 · Cited by 88
Huang, C., Soleimani, J., Herasevich, S., Pinevich, Y., Pennington, K. M., Dong, Y., Pickering, B. W., & Barwise, A. K. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.10.022 · Cited by 88
A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2
Simonis, A., Theobald, S. J., Fätkenheuer, G., Rybniker, J., & Malin, J. J. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202013105 · Cited by 87
Solomon, D. H., Bucala, R., Kaplan, M. J., & Nigrovic, P. A. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41468 · Cited by 87
Choi, S. W., Shin, J. S., Park, S., Jung, E., Park, Y.-G., Lee, J., Kim, S. J., Park, H., Lee, J., Park, S., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104955 · Cited by 86
Ocular Manifestations of COVID-19 (SARS-CoV-2): A Critical Review of Current Literature
Douglas, K. A. A., Douglas, V. P., & Moschos, M. M. (2020) · In Vivo · doi:10.21873/invivo.11952 · Cited by 85
Grinevich, V. B., Владимировна, Г. И., Doshchitsin, V. L., Kotovskaya, Y. V., Kravchuk, Y. A., Ped, V. I., Sas, E. I., Syrov, A. V., Tarasov, A. V., Tarzimanova, A. I., et al. (2020) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2020-2630 · Cited by 84
An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
Indari, O., Jakhmola, S., Manivannan, E., & Jha, H. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.632677 · Cited by 85
Canziani, L. M., Trovati, S., Brunetta, E., Testa, A., Santis, M. D., Bombardieri, E., Guidelli, G. M., Albano, G., Folci, M., Squadroni, M., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102511 · Cited by 83
Severe COVID-19: what have we learned with the immunopathogenesis?
Corrêa, B. B., Rodrigues, M. B., Cortez, A. F., Vieira, M., & Pinheiro, M. M. (2020) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-020-00151-7 · Cited by 83
Management of Arrhythmias Associated with COVID-19
Desai, A. D., Boursiquot, B. C., Melki, L., & Wan, E. Y. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01434-7 · Cited by 83
Tavares, J., Oliveira, J., Reis, P., Ribeiro, B., Silva, F., Malheiro, J., Almeida, M., Martins, L. S., Cabrita, A., Henriques, A. C., et al. (2022) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2021-0257en · Cited by 83
Dissecting the interaction between COVID‐19 and diabetes mellitus
Chee, Y. J., Tan, S. K., & Yeoh, E. C. K. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13326 · Cited by 82
Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic Strategies
Samidurai, A., & Das, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186790 · Cited by 82
Nguyen, V. T., Engleton, M., Davison, M., Ravaud, P., Porcher, R., & Boutron, I. (2021) · BMC Medicine · doi:10.1186/s12916-021-02151-w · Cited by 82
Cortegiani, A., Ippolito, M., Ingoglia, G., Iozzo, P., Giarratano, A., & Einav, S. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.06.019 · Cited by 81
Repurposing anticancer drugs for the management of COVID-19
Bairi, K. E., Trapani, D., Petrillo, A., Page, C. L., Zbakh, H., Daniele, B., Belbaraka, R., Curigliano, G., & Afqir, S. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.014 · Cited by 82
A review on potential of natural products in the management of COVID-19
Chakravarti, R., Singh, R., Ghosh, A., Dey, D., Sharma, P., Ravichandiran, V., Roy, S., & Ghosh, D. (2021) · RSC Advances · doi:10.1039/d1ra00644d · Cited by 81
Gheibi (2021) · doi:10.4103/1995-7645.318304 · Cited by 80
Chen, C., Lin, Y., Chen, T., Tseng, T.-Y., Wong, H.-L., Kuo, C.-Y., Lin, W.-P., Huang, S.-R., Wang, W., Liao, J.-H., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242763 · Cited by 80
Disease-drug and drug-drug interaction in COVID-19: Risk and assessment
Kumar, D., & Trivedi, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111642 · Cited by 80
Effectiveness of favipiravir in COVID-19: a live systematic review
Özlüşen, B., Kozan, Ş., Akcan, R. E., Kalender, M., Yaprak, D., Peltek, İ. B., Keske, Ş., Gönen, M., & Ergönül, Ö. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04307-1 · Cited by 80
D’Amico, F., Danese, S., & Peyrin‐Biroulet, L. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.003 · Cited by 79
Rosenke, K., Jarvis, M. A., Feldmann, F., Schwarz, B. H., Okumura, A., Lovaglio, J., Saturday, G. A., Hanley, P. W., Meade-White, K. D., Williamson, B. N., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.143174 · Cited by 78
Effects of hydroxychloroquine treatment on QT interval
Hooks, M. C., Bart, B. A., Vardeny, O., Westanmo, A. D., & Adabağ, S. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.06.029 · Cited by 77
Dejaco, C., Alunno, A., Bijlsma, J. W. J., Boonen, A. E. R. C. H., Combe, B. G., Finckh, A., Machado, P., Padjen, I., Sivera, F., Stamm, T., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218697 · Cited by 77
Association Between Ethnicity and Severe COVID-19 Disease: a Systematic Review and Meta-analysis
Raharja, A., Tamara, A., & Kok, L. T. (2020) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-020-00921-5 · Cited by 77
Ferraz, W. R., Gomes, R. A., Novaes, A. L. S., & Trossini, G. H. G. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0165 · Cited by 75
COVID-19 Therapeutic Options Under Investigation
Kaddoura, M., Ibrahim, M. A., Hijazi, G., Soudani, N., Audi, A., Alkalamouni, H., Haddad, S., Eid, A. H., & Zaraket, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01196 · Cited by 75
A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges
Hossen, M. S., Barek, M. A., Jahan, N., & Islam, M. S. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00485-9 · Cited by 75
Widely available lysosome targeting agents should be considered as potential therapy for COVID-19
Homolak, J., & Kodvanj, I. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106044 · Cited by 74
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs
Bartoli, A., Gabrielli, F., Alicandro, T., Nascimbeni, F., & Andreoné, P. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02569-9 · Cited by 74
Rationale for azithromycin in COVID-19: an overview of existing evidence
Gyselinck, I., Janssens, W., Verhamme, P. B., & Vos, R. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2020-000806 · Cited by 74
How to Write Statistical Analysis Section in Medical Research
Dwivedi, A. K. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2022-002479 · Cited by 74
Vannucchi, A. M., Sordi, B., Morettini, A., Nozzoli, C., Poggesi, L., Pieralli, F., Bartoloni, A., Atanasio, A., Miselli, F., Paoli, C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01018-y · Cited by 73
COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department
Singer, M. V., Brahier, T., Ngai, M., Wright, J. K., Weckman, A. M., Erice, C., Meuwly, J., Hügli, O., Kain, K. C., & Boillat‐Blanco, N. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.10.001 · Cited by 73
An overview on the treatments and prevention against COVID-19
Panahi, Y., Gorabi, A. M., Talaei, S., Beiraghdar, F., Akbarzadeh, A., Tarhriz, V., & Mellatyar, H. (2023) · Virology Journal · doi:10.1186/s12985-023-01973-9 · Cited by 73
Haque, M., Islam, S., Iqbal, S., Urmi, U. L., Kamal, Z. M., Rahman, A., Kamal, M., Haque, M., Jahan, I., Islam, M. Z., et al. (2020) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v19i0.48106 · Cited by 72
Metadata
- Authors
- Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., Labella, A., Manson, D. K., Kubin, C., Barr, R. G., Sobieszczyk, M. E., & Schluger, N. W.
- Affiliations
- Columbia University Irving Medical Center (US)
- Corresponding author
- Schluger, Neil W.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-06-18
- Volume
- 382
- Issue
- 25
- Pages
- 2411-2418
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7224609
- OpenAlex
- W3023346879
- Cited by
- 1,625
- References
- 17
- Citations by year
- 2026: 16 · 2025: 23 · 2024: 57 · 2023: 80 · 2022: 167 · 2021: 440 · 2020: 839
- FWCI
- 49.99
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (RO1-HL077612, RO1-HL093081, RO1-HL121270, RO1-LM006910)
- National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (200-2009-32593)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- hydroxychloroquine, COVID-19 pandemic, mechanical ventilation, intubation, mortality, hospitalized patients, antimalarial drugs, treatment efficacy, propensity score weighting, SARS-CoV-2
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Adult, Aged, Aged, 80 and over, Female, Hospitalization, Humans, Hydroxychloroquine, Intubation, Male, Middle Aged, New York City, Pneumonia, Viral, Treatment Failure, Coronavirus Infections, Propensity Score, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
